SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications in collaboration with researchers from Hospital Clínico San Carlos de Madrid (28)
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
2023
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
-
Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer
Current Oncology, Vol. 30, Núm. 6, pp. 5395-5408
2022
-
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Cancers, Vol. 14, Núm. 3
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
2020
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
2019
2018
-
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829
-
Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification
Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852
2017
-
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts
Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657
-
Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial (Breast Cancer Research and Treatment, (2016), 156, 3, (507-515), 10.1007/s10549-016-3792-1)
Breast Cancer Research and Treatment
-
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189
2016
-
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
Breast Cancer Research and Treatment, Vol. 156, Núm. 3, pp. 507-515
-
Review: circulating tumor cells in the practice of breast cancer oncology
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 749-759
2013
-
Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer
Oncologist, Vol. 18, Núm. 8, pp. 917-923
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
-
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132
2010
-
Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma
Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600